Artificial Intelligence in Endoscopic Ultrasound
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Endoscopic Ultrasound (EUS) is an equipment where an ultrasound transducer is attached to the tip of the endoscope. When advanced to the stomach the organs outside such as the pancreas and liver can be visualized in great detail. This enables diagnosis of conditions such as pancreatic cancer. However, an endoscopist must undergo training to accurately interpret these ultrasound images.
The investigators are in the process of developing an artificial intelligence system that could potentially interpret EUS images. The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures. Such correlation if established will lead to possible development of an artificial intelligence platform that can diagnose pancreatic diseases. Such development will potentially minimize human error and decrease learning curve to gain proficiency in EUS.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Barbara Broome
- Phone Number: 321-841-4356
- Email: barbara.broome@orlandohealth.com
Study Contact Backup
- Name: Shyam Varadarajulu, MD
- Phone Number: 321-841-2431
- Email: shyam.varadarajulu@orlandohealth.com
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32806
- Recruiting
- Orlando Health
-
Contact:
- Barbara Broome
- Phone Number: 321-841-4356
- Email: barbara.broome@orlandohealth.com
-
Contact:
- Shyam Varadarajulu, MD
- Phone Number: 321-841-2431
- Email: shyam.varadarajulu@orlandohealth.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years
- Any patient undergoing endoscopic ultrasound examination
Exclusion Criteria:
- Age < 18 years
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients undergoing endoscopic ultrasound procedures
Patients will undergo endoscopic ultrasound procedures as planned.
Abnormalities in the pancreas identified by the endoscopist during the endoscopic ultrasound examination will be correlated against those detected by the AI platform.
|
Patients will undergo endoscopic ultrasound procedures as planned.
Abnormalities in the pancreas identified by the endoscopist during the endoscopic ultrasound examination will be correlated against those detected by the AI platform.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of detection pancreatic abnormalities by AI
Time Frame: 1 day
|
Ability of AI to detect pancreatic abnormalities as identified by an endoscopist during EUS examination of the pancreas.
|
1 day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of detection pancreatic solid mass lesions by AI
Time Frame: 1 day
|
Ability of AI to detect pancreatic solid mass lesions as identified by an endoscopist during EUS examination of the pancreas.
|
1 day
|
|
Rate of detection pancreatic cystic lesions by AI
Time Frame: 1 day
|
Ability of AI to detect pancreatic cystic lesions as identified by an endoscopist during EUS examination of the pancreas.
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shyam Varadarajulu, MD, Orlando Health, Digestive Health Institute
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 24.015.01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
NCT06388967RecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II
-
NCT02414100WithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
NCT07277452Not yet recruiting
-
NCT07436741Not yet recruiting
-
NCT01959672CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
NCT03825289TerminatedMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer
-
NCT02345460TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic Carcinoma
-
NCT03977233RecruitingPancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, Adult
-
NCT01954732WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
NCT00305877CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
Clinical Trials on Patients undergoing endoscopic ultrasound procedures
-
NCT07144683RecruitingColorectal Cancer | Anastomotic Leak | Diverticulitis
-
NCT03903315CompletedLung Cancer | Endobronchial Mass
-
NCT07448896Recruiting
-
NCT07289321Enrolling by invitationPerioperative Pain in Robotic Prostatectomy
-
NCT07044102CompletedPostoperative Complications
-
NCT04040842RecruitingLow Anterior Resection Syndrome
-
NCT06045143Not yet recruiting
-
NCT05341531Not yet recruitingPostoperative Delirium | Preoperative Anxiety | Inflammatory Reaction | Preoperative Sleep Disorder
-
NCT03055325CompletedInflammation | Surgery